Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. Our team's profound expertise, pioneering and proprietary ADC technology platform, enduring IP and know-how, substantial market opportunities, and strategic and effective execution position us as industry leaders in innovative cancer treatment solutions.
At Axcynsis, our groundbreaking Matrix Optimization Platform is the cornerstone of our research and development efforts. This cutting-edge platform empowers us to swiftly explore numerous linker and payload combinations alongside our proprietary antibodies. We further harness state-of-the-art technologies, including an exclusive payload library derived from an FDA-approved drug and site-specific conjugation methods. These innovations are strategically employed to enhance the safety and quality of our ADCs.
With two potential best-in-class programs on track for clinical trials by 2025 and a third program making headway toward IND status, we are poised for significant value creation and breakthroughs in cancer therapeutics.
Based in Singapore, we plan to expand our clinical development operations to the United States by 2024.
Join us on our journey to transform cancer treatment and make a meaningful impact in biotechnology. Axcynsis is at the forefront of developing life-changing ADC therapies, and we invite you to be a part of our innovative and dedicated team as we pioneer the future of cancer therapeutics.
Company Details
- Employees
- 10
- Founded
- -
- Address
- 41 Science Park Road, Singapore,117610,singapore
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.axcynsis.com
- HQ
- Singapore
Axcynsis Therapeutics Questions
Axcynsis Therapeutics's website is http://www.axcynsis.com
Axcynsis Therapeutics's LinkedIn profile is https://sg.linkedin.com/company/axcynsis-therapeutics
Axcynsis Therapeutics has
10 employees.
View email and phone details for 10
employees at Axcynsis Therapeutics.
Axcynsis Therapeutics's industry is
Biotechnology Research
Axcynsis Therapeutics's top competitors are
Lerna Biopharma,
Carmine Therapeutics,
Tikva Allocell Pte Ltd,
Trinity Innovation Bioventure Singapore,
Neurovanda Therapeutics,
Nuevocor,
Ligature Therapeutics,
Singzyme,
Carcell Biopharma,
Hummingbird Bioscience.
Axcynsis Therapeutics's categories are Biotechnology Research
Axcynsis Therapeutics's founding year is 2022
